Compare Johnson & Johnson (JNJ) vs Progressive Corp (PGR) Price & Performance

Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).

JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.

PGR trades at $218.73, up 2.15% on the day, with a bullish technical signal and strong fundamentals. Revenue has grown from $49.6B in 2022 to $87.6B in 2025, with net income reaching $11.3B. The stock is supported by a consensus price target of $222.23 and positive analyst sentiment, though RSI levels suggest some near-term overbought conditions.

The outlook for PGR is positive, driven by consistent earnings beats and robust profitability metrics like a 34.94% ROE. Risks include competitive pressures in personal auto insurance and potential market volatility. The stock offers a solid investment opportunity with upside to the price target, but investors should monitor underwriting discipline amid industry competition.